Esperion (ESPR) Therapeutics announced it has entered into a license and distribution agreement with HLS Therapeutics for the exclusive rights to commercialize NEXLETOL and NEXLIZET in Canada. Under the terms of the agreement, Esperion will receive an upfront payment, near-term milestone and tiered royalties on product sales. Esperion will be responsible for supplying finished product to HLS Therapeutics at a profitable transfer price. Under the terms of the license and distribution agreement, Esperion will grant HLS Therapeutics exclusive commercialization rights to NEXLETOL and NEXLIZET in Canada. HLS Therapeutics will be responsible for commercialization, including reimbursement and marketing. Esperion will receive an upfront payment and be eligible for milestone payments of up to approximately $5M along with tiered royalties on product sales.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion Therapeutics Reports Mixed Q1 2025 Results
- Esperion Therapeutics Reports Strong Q1 2025 Earnings
- Esperion’s Growth Potential: Buy Rating Affirmed Amid Strong Sales and Strategic Advances
- Esperion Therapeutics (ESPR) Q1 Earnings Cheat Sheet
- Esperion’s Strategic Expansion and ACLY Innovation Drive Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue